A double-blinded, placebo-controlled trial of modafinil for amphetamine withdrawal

INTERVENTION: Participants will be recruited via UnitingCare Moreland Hall and Drug and Alcohol Services, Western Hospital (DASWest). Participants will receive oral modafinil for seven days (tapering doses from 200mg for the first 5 days to 100mg for days 6 and 7). CONDITION: Amphetamine withdrawal PRIMARY OUTCOME: The two treatment groups will be compared for their symptoms of amphetamine withdrawal, including symptoms of depression and sleep disturbance, neuro‐cognitive function, as well as any potential side effects from the medication. SECONDARY OUTCOME: 1. To gain an understanding of the natural history of psychostimulant withdrawal in an inpatient setting, focusing on severity and duration of symptoms. 2. To examine the impact of offering withdrawal medication (modafinil) on retention in withdrawal treatment. INCLUSION CRITERIA: Meets the Diagnostic and Statistical Manual for Mental Disorders No. 4 (DSM‐IV) diagnosis of current amphetamine dependence, Has used amphetamines in previous 48 hours, Is seeking treatment for amphetamine dependence, Is willing and able to give informed consent.